Evidence map›Paper›PMID 40739564›Full record

ArticleJournal of nanobiotechnology2025

Nanoliposomal PD-1 antagonist target tumor-draining lymph nodes to revitalize T cells and improve anti-tumor effect in hepatocellular carcinoma.

Wanyue Cao, Kai Yang, Gaowei Jin, Qitai Chen, Zhenduo Shao, Xinjiang Lu, Guocan Yu, Tingbo Liang, Qi Zhang

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Wanyue Cao *Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, China.
Kai Yang *Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China.
Gaowei JinDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, China.
Qitai ChenDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, China.
Zhenduo ShaoDepartment of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Xinjiang LuZhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Guocan YuKey Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China. guocanyu@mail.tsinghua.edu.cn.
Tingbo LiangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, China. liangtingbo@zju.edu.cn.
Qi ZhangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, China. qi.zhang@zju.edu.cn.

Funding

National Key Research & Development Program 2020YFA0804300/2020YFA0804301National Natural Science Foundation of China 82188102National Natural Science Foundation of China 82473461Noncommunicable Chronic Diseases-National Science and Technology Major Project 2024ZD0525100/2024ZD0525103Science and Education Department of National Administration of Traditional Chinese Medicine and Zhejiang Provincial Administration of Traditional Chinese Medicine GZY-ZJ-KJ-23025
6 · The paper itself

Abstract

backgroundTumor-draining lymph nodes (TdLNs) are pivotal in tumor immunotherapy, including the action of immune checkpoint inhibitors such as PD-1/PD-L1 blockade. However, fully harnessing the therapeutic potential of TdLNs to improve clinical outcomes remains a significant challenge.

methodsA PD-1 antagonist peptide-conjugated nanoliposome (LPs) was developed to improve lymph node targeting and therapeutic efficacy. The biodistribution, lymph node accumulation, and safety of LPs were assessed using imaging, histological, and systemic analyses. Immunodeficient mouse models and lymphadenectomy were employed to confirm the mechanistic reliance on adaptive immunity and TdLNs. Bulk RNA sequencing and multicolor flow cytometry were used to investigate TdLNs function and assess CD8

resultsLPs demonstrated optimal physicochemical properties, including ideal size, serum stability, and precise TdLNs accumulation, peaking at 3 h post-administration. In two immunocompetent HCC models, LPs treatment significantly suppressed tumor growth while remodeling the TME-enhancing CD8

conclusionsTargeting PD-1 on T cells within TdLNs effectively boosts anti-tumor immunity. The modified LPs offer a potent strategy to enhance the efficacy of cancer immunotherapy.

Indexed as

Carcinoma, HepatocellularImmune Checkpoint InhibitorsLiposomesLiver NeoplasmsLymph NodesNanoparticlesProgrammed Cell Death 1 ReceptorAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansImmunotherapyMiceT-LymphocytesTumor MicroenvironmentImmune Checkpoint InhibitorsLiposomesProgrammed Cell Death 1 ReceptorHCCImmunotherapyPeptide-conjugated nanoliposomeT cell exhaustionTumor-draining lymph nodes

Identifiers

PMID40739564
PMCPMC12312484

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.